Drug intelligence / Profile preview

AM-1002

Development stage: Unknown
Lead developer: Arcadia Medicine
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

AM-1002 is a non-racemic, non-neurotoxic form of MDMA developed by Arcadia Medicine for the treatment of mental health disorders, primarily generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). It is engineered to have an improved therapeutic profile compared to traditional MDMA, with reduced neurotoxicity, lower risk of hyperthermia, and fewer cardiovascular side effects. The drug is designed for flexible dosing and a shorter time course to allow more precise therapy. Its mechanism involves selective release of serotonin and oxytocin, which are expected to drive its therapeutic effects in mental health conditions[1][2][3].

Targets

Oxytocin receptorSERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on AM-1002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AM-1002.

Explore the full profile